SR-17018 is a novel small-molecule agonist targeting the μ-opioid receptor (MOR), exhibiting a pronounced bias towards G protein signaling over β-arrestin 2 recruitment. This pharmacological profile aims to retain potent analgesic effects while mitigating common opioid-induced adverse effects such as respiratory depression, tolerance, and dependence.
Pharmacodynamics and Mechanism of Action
SR-17018’s unique action stems from its selective activation of G protein pathways associated with MOR, minimizing β-arrestin 2-mediated signaling. This bias is believed to underlie its reduced propensity for inducing respiratory depression and other side effects commonly associated with traditional opioids.
薬物動態学
- 吸収: SR-17018 demonstrates good oral bioavailability.
- 流通: It effectively crosses the blood-brain barrier, ensuring central nervous system activity.
- 代謝: The compound undergoes hepatic metabolism, primarily via cytochrome P450 enzymes.
- Elimination: SR-17018 has a half-life of approximately 6 hours, supporting twice-daily dosing regimens.
Efficacy in Preclinical Models
In various animal models, SR-17018 has shown:
- Potent antinociceptive effects comparable to morphine.
- Sustained efficacy upon repeated administration, indicating a lower tendency for tolerance development.
- Effectiveness in neuropathic pain models, such as paclitaxel-induced allodynia.
Safety Profile
Compared to traditional opioids, SR-17018 exhibits:
- Reduced respiratory depression.
- Lower incidence of constipation.
- Minimal development of physical dependence.
用法・用量
In preclinical studies, SR-17018 has been administered orally at doses ranging from 1 to 48 mg/kg, with 24 mg/kg/day being effective for sustained analgesia. However, optimal dosing in humans remains to be established through clinical trials.
副作用の可能性
While SR-17018 shows a favorable safety profile, potential side effects observed in animal studies include:
- Mild sedation.
- Gastrointestinal disturbances at higher doses.
Harm Reduction Considerations
SR-17018’s pharmacological characteristics suggest a lower abuse potential. Nonetheless, harm reduction strategies, including patient education and monitoring, remain essential to mitigate risks associated with opioid therapy.
結論
SR-17018 represents a promising advancement in opioid pharmacotherapy, offering potent analgesia with a reduced side effect burden. Ongoing research is necessary to fully elucidate its clinical potential and safety in human populations.
Note: SR-17018 is currently under preclinical investigation. Clinical efficacy and safety in humans have yet to be established.
なぜ買うのか SR-17018 RECHEMCOから？
私たちは市場で長い取引の歴史を持っているので、あなたは私たちの経験から利益を得ることができます。
★ SR-14968 がテストされ、検証された。
ビットコイン、モネロ、銀行送金など、さまざまなお支払い方法をご利用いただけます。
ご購入時にお渡しするもの SR-17018 RECHEMCOから？
- 最高級のアルミ箔入り密封袋1袋 SR-17018
• crystalline powder
- 99% 純度
レビュー
レビューはまだありません。